Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

It is important for patients that treatments for diabetes not increase cardiovascular (CV) risk. The objective of this analysis was to examine retrospectively the CV safety of exenatide BID, a GLP-1 receptor agonist approved for treating hyperglycemia in patients with type 2 diabetes not adequately...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ratner, Robert, Han, Jenny, Nicewarner, Dawn, Yushmanova, Irina, Hoogwerf, Byron J, Shen, Larry
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2011
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3070629/
https://ncbi.nlm.nih.gov/pubmed/21410975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2840-10-22
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky